Respiratory Syncytial Virus (RSV) Prevention
New products for the prevention of severe RSV disease in children have recently been approved. Pediatric practices should understand the products, when to recommend/administer them and prepare offices for their availability.
Education Opportunities: Fall Respiratory Season Webinar Series
Respiratory syncytial virus (RSV) causes acute respiratory tract infections in people of all ages and can cause severe illness in infants and children with certain health conditions. Approximately 58,000-80,000 children under the age of 5 and up to 3% of children in their first year of life are hospitalized due to RSV infection each year in the US. Most children will get an RSV infection before the age of 2 years, and approximately 20-30% of children infected will develop a lower respiratory tract infection, such as bronchiolitis or pneumonia. Reinfection is common and is usually less severe than the primary infection.
In the US, RSV typically circulates from the fall, peaks in December or January and continues through the spring. It is transmitted by direct or close contact with those infected or from touching contaminated surfaces.
RSV Prevention Products
The following are products to prevent severe RSV infection in children.
A monoclonal antibody product included in the Vaccines for Children Program and offering long-lasting protection and was recently recommended for all infants in the 2023-2024 RSV season.
A short-acting monoclonal antibody product, available since 1998 and recommended for high-risk infants and young children.
Professional Education Resources
Educating Families about RSV and Nirsevimab
The AAP offers resources to help families better understand the risks for severe RSV disease and the benefits of prevention.
Podcasts and Voices Blogs
Learn what others are saying. Listen to our podcasts and read our blog posts.
In this episode Sean O’Leary, MD, MPH, FAAP, chair of the AAP Committee on Infectious Diseases, joins hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, for an “immunizations omnibus.” He describes newly approved products to protect against RSV, COVID and pneumococcal disease, and he predicts a difficult flu season.
Pediatrics on Call|
August 29, 2023